Reversal of Thymic Stromal Lymphopoietin-Induced Airway Inflammation through Inhibition of Th2 Responses
-
- Baohua Zhou
- Immunology Program, Benaroya Research Institute , Seattle, WA 98101
-
- Mark B. Headley
- Immunology Program, Benaroya Research Institute , Seattle, WA 98101
-
- Theingi Aye
- Immunology Program, Benaroya Research Institute , Seattle, WA 98101
-
- Joel Tocker
- Department of Inflammation, Amgen , Seattle, WA 98119
-
- Michael R. Comeau
- Department of Inflammation, Amgen , Seattle, WA 98119
-
- Steven F. Ziegler
- Immunology Program, Benaroya Research Institute , Seattle, WA 98101
書誌事項
- 公開日
- 2008-11-01
- 権利情報
-
- https://academic.oup.com/pages/standard-publication-reuse-rights
- DOI
-
- 10.4049/jimmunol.181.9.6557
- 公開者
- Oxford University Press (OUP)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Lung-specific thymic stromal lymphopoietin (TSLP) expression is sufficient for the development of an asthma-like chronic airway inflammatory disease. However, the nature of the downstream pathways that regulate disease development are not known. In this study, we used IL-4- and Stat6-deficient mice to establish the role of Th2-type responses downstream of TSLP. IL-4 deficiency greatly reduced, but did not eliminate, TSLP-induced airway hyperresponsiveness, airway inflammation, eosinophilia, and goblet cell metaplasia, while Stat6 deficiency eliminated these asthma-like symptoms. We further demonstrate, using the chronic model of TSLP-mediated airway inflammation, that blockade of both IL-4 and IL-13 responses, through administration of an anti-IL-4Rα mAb, reversed asthma-like symptoms, when given to mice with established disease. Collectively these data provide insight into the pathways engaged in TSLP-driven airway inflammation and demonstrate that simultaneous blockade of IL-4 and IL-13 can reverse established airway disease, suggesting that this may be an effective approach for the therapy of Th2-mediated inflammatory respiratory disease.</jats:p>
収録刊行物
-
- The Journal of Immunology
-
The Journal of Immunology 181 (9), 6557-6562, 2008-11-01
Oxford University Press (OUP)
